Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.
Our Science
Our most advanced program is abelacimab, an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI through dual activity against both Factor XI itself and its activated form, Factor XIa. Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.
Due to prevailing fears of bleeding, effective prevention of thromboembolic events through optimal anticoagulation remains a real-world unmet need.
Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn our vision of hemostasis-sparing anticoagulation into reality.
Our Team
Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular and metabolic disease.
Our Team
Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular and metabolic disease.